Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GENETIC TECHNOLOGIES LIMITED Capital/Financing Update 2003

Jun 15, 2003

65022_rns_2003-06-15_81b93312-e544-4e44-882f-ca31094b0c05.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

June 16th, 2003

The Manager Company Announcements Office Australian Stock Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000

Dear Sir.

GTG Grants License to Inguran, of Navasota, Texas, USA.

Genetic Technologies Limited (GTG-ASX) is pleased to announce it has granted a license to its non-coding patents to Inguran LP, of Navasota, Texas, in USA.

Inguran is a provider of sophisticated services to the livestock industry in the Americas. The license granted by GTG will permit Inguran to provide various genetic testing services, including the testing for (i) genetic markers of interest, (ii) paternity and (iii) disease susceptibility, on cattle, horses and other livestock species in USA, Colombia and Brazil.

This is the third license granted by GTG to a service provider – that is, to a genetic testing laboratory performing the actual genetic tests, some of which depend upon access to GTG's inventions and patents.

The first GTG license to a service provider was in early 2002, to the Australian firm, Genetic Solutions, who paid a \$75,000 signing fee to secure a non-exclusive license for domestic livestock and aqua-culture testing.

The second GTG license to a service provider was to ARUP, of Salt Lake City, Utah, in USA, in April 2003, who paid a signing fee of US\$75,000 (some A\$125,000) to secure a non-exclusive license covering human genes and human parasites, in USA.

Under the terms of the current license to Inguran, GTG receives a signing fee of US\$150,000 (around A\$ 230,000), plus ongoing royalties on all sales and services by Inguran under the license, in USA, Colombia and Brazil.

Negotiations with other service providers are also now in progress. Further details will be reported as appropriate.

Yours faithfully,

Dr Mervyn Jacobson Executive Chairman